An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor–Refractory ALK-Positive or ROS1-Positive NSCLC
Journal
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Journal Volume
15
Journal Issue
9
Date Issued
2020
Author(s)
Zhu, Viola W
Kim, Dong-Wan
Loong, Herbert H
Nagasaka, Misako
To, Hao
Ang, Yvonne Li-En
Ock, Chan-Young
Tchekmedyian, Nishan
Ou, Sai-Hong Ignatius
Syn, Nicholas L
Reungwetwattana, Thanyanan
Soo, Ross A
Abstract
Lorlatinib, a next-generation central nervous system-penetrant ALK/ROS1 tyrosine kinase inhibitor (TKI), is approved to treat TKI-refractory ALK-positive (ALK+) NSCLC based on results from a phase 2 study.
Subjects
ALK; Expanded access; Lorlatinib; NSCLC; ROS1; TKI-refractory
SDGs
Other Subjects
alanine aminotransferase; anaplastic lymphoma kinase; ceritinib; crizotinib; lorlatinib; protein tyrosine kinase; protein tyrosine kinase inhibitor; receptor tyrosine kinase 1; unclassified drug; lorlatinib; macrocyclic lactam; oncoprotein; protein kinase inhibitor; protein tyrosine kinase; ROS1 protein, human; adult; aged; ALK gene; Article; blurred vision; body weight disorder; brain metastasis; carcinomatous meningitis; clinical trial; cognitive defect; cohort analysis; constipation; depression; dizziness; drug efficacy; drug response; drug safety; dry eye; edema; enzyme activity; fatigue; female; gait disorder; genetic analysis; hallucination; hemorrhoid; human; hypercholesterolemia; hypertransaminasemia; hypertriglyceridemia; major clinical study; male; median survival time; multicenter study; myalgia; non small cell lung cancer; peripheral neuropathy; pneumonia; priority journal; progression free survival; rash; ROS1 gene; side effect; treatment duration; tumor-related gene; genetics; Hong Kong; lung tumor; South Korea; Taiwan; Hong Kong; Humans; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Republic of Korea; Taiwan
Type
journal article